Research

MGN3

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Indication: Cancer

Source: 3rd Annual Meeting of the Japanese Society of Complementary & Alternative Medicine

Research: Over 200 patients with a variety of terminal cancers were evaluated for 18 months. Patients were given MGN3, a patented formula of rice bran hydrolyzed with shiitake mushroom extracts.

Results: Patients given MGN3 plus conventional therapies recorded a 59% survival rate, while those on conventional therapies alone recorded a 34% survival rate. Additionally, patients whose natural killer (NK) cell activity increased 40% or more during the study recorded a survival rate of 81%.

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters